

## HR 4619

Pharmaceutical REPAI Act

**Congress:** 116 (2019–2021, Ended)

**Chamber:** House

**Policy Area:** Health

**Introduced:** Oct 8, 2019

**Current Status:** Referred to the Subcommittee on Health.

**Latest Action:** Referred to the Subcommittee on Health. (Oct 9, 2019)

**Official Text:** <https://www.congress.gov/bill/116th-congress/house-bill/4619>

### Sponsor

**Name:** Rep. Schakowsky, Janice D. [D-IL-9]

**Party:** Democratic • **State:** IL • **Chamber:** House

### Cosponsors (2 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Higgins, Brian [D-NY-26]	D · NY		Oct 8, 2019
Rep. Wild, Susan [D-PA-7]	D · PA		Oct 8, 2019

### Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred to	Oct 9, 2019
Ways and Means Committee	House	Referred to	Oct 8, 2019

### Subjects & Policy Tags

**Policy Area:**

Health

### Related Bills

Bill	Relationship	Last Action
116 HR 3	Related bill	<b>Sep 8, 2020:</b> Read the second time. Placed on Senate Legislative Calendar under General Orders. Calendar No. 521.

### Summary (as of Oct 8, 2019)

#### Pharmaceutical Rebates for Excessive Pricing Above Inflation Act or the Pharmaceutical REPAI Act

This bill requires drug manufacturers, subject to civil penalties, to issue rebates to the Centers for Medicare & Medicaid Services for covered drugs under the Medicare prescription drug benefit that cost \$100 or more and for which the average manufacturer price increases faster than inflation.

## Actions Timeline

---

- **Oct 9, 2019:** Referred to the Subcommittee on Health.
- **Oct 8, 2019:** Introduced in House
- **Oct 8, 2019:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
- **Oct 8, 2019:** Referred to the Subcommittee on Health.